Press Releases

Endonovo Therapeutics Announces Strategic Relationship with US Authentic Trading Company

Download PDF

LOS ANGELES, CA, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapies, today announced the company has entered into a non-binding Letter of Intent for a strategic partnership with US Authentic Trading Company (USAT) to act as the exclusive partner to assist with facilitating a relationship between the Company and China.

Endonovo is among 14 other United States based medical device developers chosen by USAT to handle the distribution into China’s hospital network.

USAT has access for accelerated ‘green channel’ medical device approvals and registrations, clinical trial consultative authority and implementation logistics in mainland China.

The company anticipates definitive agreements to be executed in the first quarter of 2019.

Alan Collier, CEO of Endonovo Therapeutics, stated, “With nearly eight million hospital beds in China and the increased costs and health risks associated with opioid use, I am pleased to be working with the US Authentic Trading Company to ensure SofPulse® is available throughout mainland China. The positive results in reducing pain and edema, combined with eliminating opioid use and dependency is something we are very proud of. We believe that hospitals, treatment centers and medical facilities throughout the World will benefit with SofPulse®.”

Lucia Fields, Managing Partner for Origenetics™ stated, “We are so excited to be working with Endonovo Therapeutics and their innovative medical approach to pain therapy. Introducing them to our partner USAT was a real win-win. SofPulse® is an amazing solution at the center of one of the fastest growing health issues—opioid addiction.”

About US Authentic Trading Company

US Authentic Trading Co., or USAT ( is a company based in Los Angeles, CA with a mission to facilitate select small to medium sized clients with entry into the coveted Chinese marketplace. USAT’s aim is to provide a level playing field in China for innovative products to compete with global multi-billion dollar corporations in the healthcare space. USAT offers services such as importation licenses, bonded warehouses, product registrations and sales permits, turnkey marketing and sales and expedited access to the CFDA approval process.

The USAT Shanghai Medical Device Display Center in the Waigaoqiao Free Trade Zone provides access to an audience of purchasing agents from Chinese national and private hospitals and clinics. USAT’s relationships in China provide IP and anti-counterfeiting protection on par with advanced Western markets. For additional information please refer to USAT’s website ( ) or call Marco Rosenbaum, VP for Business Development, at 310-890-8143.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ Therapies addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ System device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals™ addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's non-invasive, wearable Electroceuticals™ work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur.

About Origenetics Innovations, LLC

Origenetics™ Innovations, LLC offers a global brand for products and services related to emerging medical technologies. Uniquely placed with deep experience in health care, product sourcing, retail placement and market innovation in the U.S and Asia, Origenetics™ consults, connects and supports strategic partnerships and innovative products for world-wide marketplace success, while redefining health care.

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Investor Relations Contact: 

Endonovo Therapeutics, Inc. 
Mr. Andrew Barwicki


Source: Endonovo Therapeutics, Inc.